Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

4 Nov 2019

Abstract excerpt

Incorporation of asparaginase (ASNase) and pegylated asparaginase (PEG-ASP) into pediatric-inspired regimens for adults with acute lymphoblastic leukemia (ALL) has led to improved treatment outcomes albeit with increased toxicities. This study compared the efficacy and safety of the Children’s Oncology Group standard PEG-ASP (SD) dosing (>1000, median 2500 IU/m2/dose) in adult Philadelphia chromosome-negative ALL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Adolescent and Pediatric Healthcare
Share to Childhood Cancer Survivors' Quality of Life

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31680584
DOI: 10.1080/10428194.2019.1680839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaPMID 31680584Read ↗

Update on the Use of L-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetic markers of PEG-asparaginase toxicity in Brazilian pediatric ALL: insights from a multicenter prospective cohort study.Semantic proximity Read ↗

Biogeneric native and polyethylene glycol-conjugated <i>E. coli</i> asparaginases for treating children with acute lymphoblastic leukaemiaSemantic proximity Read ↗

Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemiaSemantic proximity Read ↗

Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study.Semantic proximity Read ↗

Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-AsparaginaseSemantic proximity Read ↗

Association of aberrantASNSimprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALLSemantic proximity Read ↗

Asparagine Synthetase ChemotherapySemantic proximity Read ↗

Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation.Semantic proximity Read ↗

Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.